Abstract
Purpose
Hydration is needed before and after cisplatin infusion for reducing the risk of nephrotoxicity. Even though there is no standard regimen, patients receive mostly intravenous hydration before and after cisplatin leading hospitalization during at least one night. Since the feasibility has been published, oral hydration after cisplatin was implemented in our practice. The safety of this new way of hydration needs to be assessed in clinical practice.
Methods
We collected medical records from patients treated by cisplatin for lung cancer in our unit between 2010 and 2016. We retrospectively analyzed the incidence of cisplatin induced nephrotoxicity between after and before the change of hydration regimen.
Results
Our patient cohort included 241 patients hydrated by intravenous regimen (IV/IV group) and 276 patient hydrated by intravenous and oral regimen (IV/PO group). Grade ≥ 1 nephrotoxicity occurred in 39.4 and 25.7% in the IV/IV and IV/PO groups respectively (p = 0.001). Age over 70 at baseline was a predictive factor for nephrotoxicity, but not estimated glomerular filtration rate nor cisplatin-associated drugs. After a multivariate analysis, age remained a predictive factor for nephrotoxicity and IV/PO hydration associated with a decrease in nephrotoxic risk.
Conclusion
The implementation of oral hydration in our practice was not associated with an increase in nephrotoxicity. Our observation based on large data from clinical practice shows that oral hydration after cisplatin is safe.
Similar content being viewed by others
References
Masters GA, Temin S, Azzoli CG, Giaccone G, Baker S Jr, Brahmer JR, Ellis PM, Gajra A, Rackear N, Schiller JH, Smith TJ, Strawn JR, Trent D, Johnson DH, American Society of Clinical Oncology Clinical Practice (2015) Systemic therapy for stage IV non–small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 33(30):3488–3515. https://doi.org/10.1200/JCO.2015.62.1342
Facchetti G, Petrella F, Spaggiari L, Rimoldi I (2017) Malignant pleural mesothelioma: state of the art and advanced cell therapy. Eur J Med Chem 142:266–270. https://doi.org/10.1016/j.ejmech.2017.07.063
Kalemkerian GP (2014) Advances in pharmacotherapy of small cell lung cancer. Expert Opin Pharmacother 15(16):2385–2396. https://doi.org/10.1517/14656566.2014.957180
Miller RP, Tadagavadi RK, Ramesh G, Reeves WB (2010) Mechanisms of cisplatin nephrotoxicity. Toxins 2(11):2490–2518. https://doi.org/10.3390/toxins2112490
Pabla N, Dong Z (2008) Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. Kidney Int 73(9):994–1007. https://doi.org/10.1038/sj.ki.5002786
Oh G-S, Kim H-J, Shen A, Lee SB, Khadka D, Pandit A, So HS (2014) Cisplatin-induced kidney dysfunction and perspectives on improving treatment strategies. Electrolyte Blood Press E BP 12(2):55–65. https://doi.org/10.5049/EBP.2014.12.2.55
Launay-Vacher V, Rey J-B, Isnard-Bagnis C, Deray G, Daouphars M (2008) European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Prevention of cisplatin nephrotoxicity: state of the art and recommendations from the European Society of Clinical Pharmacy Special Interest Group on Cancer Care. Cancer Chemother Pharmacol 61(6):903–909. https://doi.org/10.1007/s00280-008-0711-0
Fukushima K, Okada A, Oe H, Hirasaki M, Hamori M, Nishimura A, Shibata N, Sugioka N (2018 Apr) Pharmacokinetic-pharmacodynamic analysis of cisplatin with hydration and mannitol diuresis: the contribution of urine cisplatin concentration to nephrotoxicity. Eur J Drug Metab Pharmacokinet 43(2):193–203. https://doi.org/10.1007/s13318-017-0436-8
Stewart DJ, Dulberg CS, Mikhael NZ, Redmond MD, Montpetit VA, Goel R (1997) Association of cisplatin nephrotoxicity with patient characteristics and cisplatin administration methods. Cancer Chemother Pharmacol 40(4):293–308. https://doi.org/10.1007/s002800050661
Lavolé A, Danel S, Baudrin L et al (2012) Routine administration of a single dose of cisplatin ≥75mg/m2 after short hydration in an outpatient lung-cancer clinic. Bull Cancer (Paris) (4):43–48. https://doi.org/10.1684/bdc.2012.1555
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D (1999) A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med 130(6):461–470
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P (2004) Acute dialysis quality initiative workgroup. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care Lond Engl 8(4):R204–R212. https://doi.org/10.1186/cc2872
Willox JC, McAllister EJ, Sangster G, Kaye SB (1986) Effects of magnesium supplementation in testicular cancer patients receiving cis-platin: a randomised trial. Br J Cancer 54(1):19–23
Bodnar L, Wcislo G, Gasowska-Bodnar A, Synowiec A, Szarlej-Wcisło K, Szczylik C (2008) Renal protection with magnesium subcarbonate and magnesium sulphate in patients with epithelial ovarian cancer after cisplatin and paclitaxel chemotherapy: a randomised phase II study. Eur J Cancer Oxf Engl 1990 44(17):2608–2614. https://doi.org/10.1016/j.ejca.2008.08.005
Furukawa N, Kawaguchi R, Kobayashi H (2012) Use of high-dose cisplatin with aprepitant in an outpatient setting. Eur J Cancer Care (Engl) 21(4):436–441. https://doi.org/10.1111/j.1365-2354.2011.01284.x
Reece PA, Stafford I, Russell J, Khan M, Gill PG (1987) Creatinine clearance as a predictor of ultrafilterable platinum disposition in cancer patients treated with cisplatin: relationship between peak ultrafilterable platinum plasma levels and nephrotoxicity. J Clin Oncol 5(2):304–309. https://doi.org/10.1200/JCO.1987.5.2.304
Sassier M, Dugué AE, Clarisse B, Lesueur P, Avrillon V, Bizieux-Thaminy A, Auliac JB, Kaluzinski L, Tillon J, Robinet G, le Caer H, Monnet I, Madroszyk A, Boza G, Falchero L, Fournel P, Egenod T, Toffart AC, Leiber N, Do P, Gervais R (2015) Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting. Lung Cancer 89(2):161–166. https://doi.org/10.1016/j.lungcan.2015.05.005
Madias NE, Harrington JT (1978) Platinum nephrotoxicity. Am J Med 65(2):307–314
Sato K, Watanabe S, Ohtsubo A et al (2016) Nephrotoxicity of cisplatin combination chemotherapy in thoracic malignancy patients with CKD risk factors. BMC Cancer 16(1). https://doi.org/10.1186/s12885-016-2271-8
Tiseo M, Martelli O, Mancuso A, Sormani MP, Bruzzi P, di Salvia R, de Marinis F, Ardizzoni A (2007) Short hydration regimen and nephrotoxicity of intermediate to high-dose cisplatin-based chemotherapy for outpatient treatment in lung cancer and mesothelioma. Tumori 93(2):138–144
Ouchi A, Asano M, Aono K, Watanabe T, Kato T (2014) Comparison of short and continuous hydration regimen in chemotherapy containing intermediate- to high-dose cisplatin. J Oncol 2014:1–4. https://doi.org/10.1155/2014/767652
Yamaguchi T, Uozu S, Isogai S, Hayashi M, Goto Y, Nakanishi T, Imaizumi K (2017) Short hydration regimen with magnesium supplementation prevents cisplatin-induced nephrotoxicity in lung cancer: a retrospective analysis. Support Care Cancer 25(4):1215–1220. https://doi.org/10.1007/s00520-016-3512-8
Hotta K, Takigawa N, Hisamoto-Sato A, Ichihara E, Kudo K, Uchida K, Yanase-Nakamura K, Tanaka H, Kato Y, Tabata M, Tanimoto M, Kiura K (2013) Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung Cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol 43(11):1115–1123. https://doi.org/10.1093/jjco/hyt128
Ninomiya K, Hotta K, Hisamoto-Sato A, Ichihara E, Gotoda H, Morichika D, Tamura T, Kayatani H, Minami D, Kubo T, Tabata M, Tanimoto M, Kiura K (2016) Short-term low-volume hydration in cisplatin-based chemotherapy for patients with lung cancer: the second prospective feasibility study in the Okayama Lung Cancer Study Group Trial 1201. Int J Clin Oncol 21(1):81–87. https://doi.org/10.1007/s10147-015-0860-1
Horinouchi H, Kubota K, Itani H, Taniyama TK, Nakamichi S, Wakui H, Kanda S, Nokihara H, Yamamoto N, Sekine I, Tamura T (2013) Short hydration in chemotherapy containing cisplatin (>=75 mg/m2) for patients with lung cancer: a prospective study. Jpn J Clin Oncol 43(11):1105–1109. https://doi.org/10.1093/jjco/hyt122
Sato J, Morikawa N, Nitanai H et al (2016) Feasibility study of short hydration using oral rehydration solution in cisplatin including chemotherapy of lung cancer. J Pharm Health Care Sci 2(1). https://doi.org/10.1186/s40780-016-0041-z
Mor V, Stalker MZ, Gralla R, Scher HI, Cimma C, Park D, Flaherty AM, Kiss M, Nelson P, Laliberte L, Schwartz R, Marks PA, Oettgen HF (1988) Day hospital as an alternative to inpatient care for cancer patients: a random assignment trial. J Clin Epidemiol 41(8):771–785
Azzoli CG, Baker S, Temin S et al (2009) American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(36):6251–6266. https://doi.org/10.1200/JCO.2009.23.5622
Azuma T, Matayoshi Y, Sato Y, Sato Y, Nagase Y, Oshi M (2016) The safety and effect of chemotherapy with short hydration for urothelial cancer on patients’ quality of life. Jpn J Clin Oncol 46(10):958–963. https://doi.org/10.1093/jjco/hyw097
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
This study was performed in the respect for ethical consideration of research involving human participant. Since it was a retrospective study based on existing data, formal consent is not required.
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Puisset, F., Bigay-Game, L., Paludetto, M.N. et al. Safety of oral hydration after cisplatin infusion in an outpatient lung cancer unit. Support Care Cancer 27, 1679–1686 (2019). https://doi.org/10.1007/s00520-018-4415-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-018-4415-7